Table 1 Demographics and clinical characteristics of participants
From: T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?
Variable | SLE patients | Healthy controls | |
|---|---|---|---|
|  | (n = 25) | (n = 15) | |
| Â | IFN type I negative | IFN type I positive | Â |
|  | (n = 9) | (n = 16) |  |
Demographics | Â | Â | Â |
   Number of females, n (%) | 9/9 (100%) | 14/16 (88%) | 15/15 (100%) |
   Age (years) | 41.3 ± 17.5 | 39.8 ± 15.7 | 41.0 ± 14.0 |
   Race, n (%) |  |  |  |
   Caucasian | 8/9 (89%) | 7/16 (44%) | 15/15 (100%) |
   Black | 0/9 (0) | 8/16 (50%) | 0/15 (0) |
   Asian | 0/9 (0) | 0/16 (0) | 0/15 (0) |
   Mixed race | 1/9 (11%) | 1/16 (6%) | 0/15 (0) |
Clinical | Â | Â | Â |
   Disease duration (years) | 12.1 ± 8.0 | 14.4 ± 11.3 | - |
   Mucocutaneous, n (%) | 3/9 (33%) | 10/16 (63%) | - |
   Arthritis, n (%) | 7/9 (78%) | 6/16 (38%) | - |
   Serositis, n (%) | 1/9 (11%) | 3/16 (19%) | - |
   Nephritis, n (%) | 3/9 (33%) | 9/16 (56%) | - |
   Neuropsychiatric, n (%) | 1/9 (11%) | 3/16 (19%) | - |
   Hematologic, n (%) | 6/9 (67%) | 12/16 (75%) | - |
Laboratory | Â | Â | Â |
   ANA positivity, n (%) | 9/9 (100%) | 16/16 (100%) | - |
   Anti-ds-DNA positivity, n (%) | 5/9 (56%) | 10/16 (63%) | - |
Treatment | Â | Â | Â |
   Hydroxychloroquine, n (%) | 7/9 (78%) | 11/16 (69%) | - |
   Corticosteroids, n (%) | 5/9 (56%) | 10/16 (63%) | - |
   Mycophenolate mofetil, n (%) | 0/9 (0) | 4/16 (25%) | - |
   Azathioprine, n (%) | 2/9 (22%) | 3/16 (19%) | - |
   Cyclophosphamide, n (%) | 0/9 (0) | 1/16 (6%) | - |